These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 33792840

  • 1. A new antisarcoma strategy: multisubtype heat shock protein/peptide immunotherapy combined with PD-L1 immunological checkpoint inhibitors.
    Li H, Sui X, Wang Z, Fu H, Wang Z, Yuan M, Liu S, Wang G, Guo Q.
    Clin Transl Oncol; 2021 Aug; 23(8):1688-1704. PubMed ID: 33792840
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma.
    Guo QY, Yuan M, Peng J, Cui XM, Song G, Sui X, Lu SB.
    J Exp Clin Cancer Res; 2011 Feb 26; 30(1):24. PubMed ID: 21352555
    [Abstract] [Full Text] [Related]

  • 3. Prophylactic Antitumor Effect of Mixed Heat Shock Proteins/Peptides in Mouse Sarcoma.
    Wang Y, Liu SY, Yuan M, Tang Y, Guo QY, Cui XM, Sui X, Peng J.
    Chin Med J (Engl); 2015 Aug 20; 128(16):2234-41. PubMed ID: 26265619
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Progress and opportunities for immune therapeutics in osteosarcoma.
    Lettieri CK, Appel N, Labban N, Lussier DM, Blattman JN, Hingorani P.
    Immunotherapy; 2016 Oct 20; 8(10):1233-44. PubMed ID: 27605071
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A Review of T-Cell Related Therapy for Osteosarcoma.
    Yoshida K, Okamoto M, Aoki K, Takahashi J, Saito N.
    Int J Mol Sci; 2020 Jul 10; 21(14):. PubMed ID: 32664248
    [Abstract] [Full Text] [Related]

  • 12. Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors.
    Salewski I, Kuntoff S, Kuemmel A, Feldtmann R, Felix SB, Henze L, Junghanss C, Maletzki C.
    Cancer Immunol Immunother; 2021 Dec 10; 70(12):3405-3419. PubMed ID: 33870463
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8.
    Tadano H, Tsukahara T, Mizushima E, Akamatsu A, Watanabe K, Nojima I, Kubo T, Kanaseki T, Hirohashi Y, Sato N, Torigoe T.
    Br J Cancer; 2020 Oct 10; 123(9):1387-1394. PubMed ID: 32753678
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
    Hennessy M, Wahba A, Felix K, Cabrera M, Segura MG, Kundra V, Ravoori MK, Stewart J, Kleinerman ES, Jensen VB, Gopalakrishnan V, Pena R, Quach P, Kim G, Kivimäe S, Madakamutil L, Overwijk WW, Zalevsky J, Gordon N.
    Int J Cancer; 2021 Apr 15; 148(8):1928-1937. PubMed ID: 33152115
    [Abstract] [Full Text] [Related]

  • 20. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, Lee JH, Rabizadeh S, Soon-Shiong P, Schlom J, Hodge JW.
    J Immunother Cancer; 2020 May 15; 8(1):. PubMed ID: 32439799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.